
Aplidine
CAS No. 137219-37-5
Aplidine( Plitidepsin )
Catalog No. M28854 CAS No. 137219-37-5
Aplidine possesses antiviral activity against SARS-CoV-2(IC90 = 0.88 nM). Aplidine is a potent anti-cancer agent by targeting eukaryotic translation elongation factor 1 Alpha 2(EEF1A2, Kd = 80?nM).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 655 | Get Quote |
![]() ![]() |
10MG | 888 | Get Quote |
![]() ![]() |
25MG | 1377 | Get Quote |
![]() ![]() |
50MG | 1782 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameAplidine
-
NoteResearch use only, not for human use.
-
Brief DescriptionAplidine possesses antiviral activity against SARS-CoV-2(IC90 = 0.88 nM). Aplidine is a potent anti-cancer agent by targeting eukaryotic translation elongation factor 1 Alpha 2(EEF1A2, Kd = 80?nM).
-
DescriptionAplidine possesses antiviral activity against SARS-CoV-2(IC90 = 0.88 nM). Aplidine is a potent anti-cancer agent by targeting eukaryotic translation elongation factor 1 Alpha 2(EEF1A2, Kd = 80?nM).(In Vitro):In hACE2-293T cells, Aplidine exhibits anti–SARS-CoV-2 activity with an IC90 of 0.88 nM. In an established model of human pneumocyte-like cells, Aplidine inhibits SARS-CoV-2 replication with an IC90 of 3.14 nM and a selectivity index of 40.4. Aplidine (20 nM; 1 h) induces a dose-dependent decrease in VEGF secretion in MOLT-4 cells. Aplidine (20 nM; 1 h) does not result in significant inhibition of VEGF-R1 mRNA in normal endothelial cells, which do express VEGFR-1 but do not secrete VEGF.(In Vivo):In BALB/c mice expressing human ACE2, Aplidine significantly reduced SARS-CoV-2 infection. 0.3 mg/kg Aplidine group results in a reduction of nearly 2 log units in SARS-CoV-2 viral titers in the lungs, and the 1 mg/kg group leads to a reduction of 1.5 log units.
-
In Vitro——
-
In VivoAnimal Model:BALB/c mice Dosage:0.3 mg/kg; 1 mg/kg Administration:1 day QD at 1 mg/kg; 3days QD at 0.3 mg/kg Result:Showed in vivo antiviral efficacy in mouse models of SARS-CoV-2 infection.
-
SynonymsPlitidepsin
-
PathwayOthers
-
TargetOther Targets
-
RecptorEP1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number137219-37-5
-
Formula Weight1110.34
-
Molecular FormulaC57H87N7O15
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (90.06 mM)
-
SMILESCC[C@@H]([C@@H]1[C@@H](O)CC(O[C@@H](C(C)C)C([C@H](C)C(N[C@@H](CC(C)C)C(N2CCC[C@H]2C(N(C)[C@@H](CC3=CC=C(OC)C=C3)C(O[C@H](C)[C@H](NC([C@H](N(C([C@@H]4CCCN4C(C(C)=O)=O)=O)C)CC(C)C)=O)C(N1)=O)=O)=O)=O)=O)=O)=O)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.McKeown SC, et al. Identification of novel pyrazole acid antagonists for the EP1 receptor. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4767-7Epub 2006 Jul 14.
molnova catalog



related products
-
DMHCA
DMHCA is a selective LXR agonist with anti-inflammatory activity, which induces ABCA1 expression and upregulates FASN and SREBP-1alpha gene expression.
-
Dipotassium tetrachl...
Dipotassium tetrachloroplatinate (Potassium tetrachloroplatinate) exhibits antitumor activity in solid tumor lines and can be used in the treatment of oncological diseases.
-
Etrolizumab
Etrolizumab (rhuMAb Beta7), a gut-selective anti-β7 integrin monoclonal antibody, targets the β7 subunit of α4β7 and αEβ7 integrins specifically, demonstrating affinity with K i values of 18 nM for Human α4β7 and 1800 pM for Human αEβ7-293.